Claims
- 1. A solution comprising interleukin-13 (IL-13), wherein IL-13 comprises amino acid residues 1-113 of FIG. 2, IL-13 is either unlabeled, 15N enriched or 15N,13C enriched, IL-13 comprises four alpha helices αA, αB, αC and αD, and two beta strands β1 and β2, and αA comprises amino acid residues P6-Q22 of IL-13, β1 comprises M33-W35 of IL-13, αB comprises amino acid residues M43-152 of IL-13, αC comprises amino acid residues A59-F70 of IL-13, β2 comprises amino acid residues K89-E91 of IL-13, and αD comprises amino acid residues V92-R108 of IL-13.
- 2. The solution of claim 1, wherein IL-13 has the structure defined by the relative structural coordinates according to FIG. 8, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å.
- 3. The solution of claim 1, wherein IL-13 has the structure defined by the relative structural coordinates according to FIG. 8, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.0 Å.
- 4. The solution of claim 1, wherein IL-13 has the structure defined by the relative structural coordinates according to FIG. 8, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 0.5 Å.
- 5. A structural model of IL-13 comprising the relative structural coordinates according to FIG. 8 or 9 of IL-13, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å.
- 6. The model of claim 5, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 1.0 Å.
- 7. The model of claim 5, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 0.5 Å.
- 8. An active site of IL-13, wherein said active site is characterized by a three dimensional structure comprising the relative structural coordinates of amino acid residues A9, E12, E15, E16 and M66 of IL-13 according to FIG. 8 or 9, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å.
- 9. The active site of claim 8, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 1.0 Å.
- 10. The active site of claim 8, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 0.5 Å.
- 11. An active site of IL-13, wherein said active site is characterized by a three dimensional structure comprising the relative structural coordinates of amino acid residues I52, Q64, R65 and M66 of IL-13 according to FIG. 8 or 9, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å.
- 12. The active site of claim 11, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 1.0 Å.
- 13. The active site of claim 11, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 0.5 Å.
- 14. A method for designing an agent that interacts with IL-13, comprising the steps of:
(a) generating a three dimensional model of IL-13 using the relative structural coordinates of the amino acids of FIG. 8 or 9, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å; and (b) employing said three-dimensional model to design an agent that interacts with IL-13.
- 15. The method of claim 14, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 1.0 Å.
- 16. The method of claim 14, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 0.5 Å.
- 17. The method of claim 14, wherein the agent is designed using an active site of IL-13.
- 18. The method of claim 17, wherein the active site comprises the relative structural coordinates of amino acid residues A9, E12, E15, E16 and M66 of IL-13 according to FIG. 8 or 9, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å.
- 19. The method of claim 18, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 1.0 Å.
- 20. The method of claim 18, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 0.5 Å.
- 21. The method of claim 17, wherein the active site comprises the relative structural coordinates of amino acid residues I52, Q64, R65 and M66 of IL-13 according to FIG. 8 or 9, ± a root mean square deviation from the conserved backbone atoms of said amino acids of not more than 1.5 Å.
- 22. The method of claim 21, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 1.0 Å.
- 23. The method of claim 21, wherein the ± a root mean square deviation from the conserved backbone atoms of said amino acids is not more than 0.5 Å.
- 24. The method according to claim 14, wherein the step of employing the three dimensional structure to design an agent comprises the steps of:
(a) identifying chemical entities or fragments capable of associating with IL-13; and (b) assembling the identified chemical entities or fragments into a single molecule to provide the structure of the agent.
- 25. The method according to claim 14, wherein the agent is designed de novo.
- 26. The method according to claim 14, wherein the agent is designed from a known agent.
- 27. The method of claim 14, further comprising the step of obtaining or synthesizing the agent.
- 28. The method of claim 27, wherein the agent obtained or synthesized in is contacted with IL-13 in order to determine the effect the agent has on IL-13.
- 29. An agent designed by the method of claim 14.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application No. 60/296,607 filed Jun. 7, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60296607 |
Jun 2001 |
US |